This commentary highlights the major points raised by a recent study investigating the effect of anti-rheumatic drugs used for the treatment of rheumatoid arthritis (RA) in reducing the risk for Parkinson’s disease (PD). Several studies in the past have assessed the effect of anti-rheumatic drugs used for the treatment of RA in lowering the risk of incident PD, but the results have been inconsistent. Those studies left unanswered the question as to whether the reported risk reduction is independent of treatment with disease modifying anti-rheumatic drugs (DMARDs) or not. Several of the reported data indicate that DMARDs appear to further reduce this risk. We raise several points that we think must be taken into account in future studies and emphasize the need for continuous research to explore the underlying mechanism, which could be responsible for the presumed reduced risk for PD development in RA patients treated with specific biologics.
Primary Content – Primary Content Goes Here.
Close
Τα cookies είναι σημαντικά για την εύρυθμη λειτουργία του ιστοτόπου και την βελτίωση της online εμπειρίας σας. Πατήστε "Αποδοχή" για να συνεχίσετε!
